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DDiscussion
Dr John J. Lamberti (San Diego, Calif). I compliment Dr Oppido
for his excellent presentation. Oppido and colleagues have analyzed
their experience in repairing anatomic mitral valves. Seventy of 71
patients underwent successful valve repair, with a relatively small
percentage returning for early re-repair. In general, I agree with their
indications for surgery and many of the technical details described in
the article.
Oppido and colleagues favor exposure through a conventional
left atriotomy. I prefer the transseptal approach, and I have a very
low threshold for extending my incision into the dome of the left
atrium, thereby creating optimal exposure of the valve, especially
in small patients. Intraoperative valve testing requires that the valve
be undistorted while static testing is taking place.
Dr Oppido didn’t mention in his presentation, but transesopha-
geal echocardiography was used in about 87% of their cases. We
rely heavily on the postrepair transesophageal echocardiography
in determining whether our repair is adequate. In complex repairs,
we recommend performing a preliminary transesophageal echocar-
diogram after recovery of the myocardium has occurred but not nec-
essarily before full rewarming has been completed. In about 10% of
patients, we may go back to bypass and make adjustments to the re-
pair. This approach allows fine-tuning of the repair. We always
place a left atrial pressure monitoring catheter before separation
from bypass. The postrepair analysis must be performed under
optimal loading conditions if we are to make inferences about the
quality and durability of the repair.
Most of the early reoperations in Oppido and colleagues’ series
occurred in patients younger than 1 year. Only 87% of the patients
underwent transesophageal echocardiography at the time of the first
repair. In our experience, analysis of the repair in the operating
room is very important in predicting short- and long-term out-
comes. When a patient is too small for a transesophageal echocar-
diographic probe, we use epicardial echocardiography to analyze
the repair. We assume that the quality of the repair will never be
better than as seen on the immediate postrepair transesophageal
echocardiogram. The predischarge transesophageal echocardio-
gram often shows a little worse regurgitation. We integrate our op-
erative findings with those of the postrepair transesophageal
echocardiogram, and on a few occasions we’ve been able to modify
the repair to improve function.
We agree with Oppido and colleagues that a very eclectic ap-
proach must be taken to repair the unusual pathology encountered
in patients born with congenital abnormalities of the mitral valve.
Oppido and colleagues have demonstrated that most abnormal
mitral valves can be salvaged. In the future, preoperative 3-dimen-
sional echocardiography could be useful in planning repair strate-
gies. We don’t have that available at our institution.
The goal of this surgery, as clearly stated by Oppido and col-
leagues, is not cure but postponement of mitral valve replacement
as long as possible. I have several questions.1320 The Journal of Thoracic and Cardiovascular Surgery c JFirst, Dr Oppido, did you use epicardial echocardiography in
those patients for whom transesophageal echocardiography was
not available?
Dr Oppido. Yes. We strongly believe, as you do, that transeso-
phageal echocardiography is the criterion standard for intraoperative
evaluation before repair, to inform an appropriate repair, and to
check the immediate result of the repair. As for the patients who
didn’t undergo transesophageal echocardiography, they did undergo
epicardial echocardiography.
DrLamberti.Was any valve revised in the operating room on the
basis of the postrepair transesophageal or epicardial echocardiogram?
Dr Oppido. Yes, we revised the repair in approximately 10% of
the patients on the basis of what we saw on the transesophageal
echocardiogram.
Dr Lamberti. So actually, all the patients had some form of
echocardiography in the operating room?
Dr Oppido. Yes.
Dr Lamberti. In reading the article, that wasn’t clear, and I was
wondering whether the early failures correlated with patients who
did not have an echocardiogram before leaving the operating room.
Dr Oppido. All the patients underwent either transesophageal
echocardiography (which was done in nearly all patients, 87%) or
epicardial echocardiography.
Dr Lamberti. Thank you. It’s an excellent article.
Dr Rodolfo Neirotti (Cambridge, Mass). I agree that annulo-
plasty techniques involving a ring can be a problem in the pediatric
population. Although rigid and flexible rings meet the needs of
adults, they do not allow room for growth of the native annulus
when implanted in children. I think that biodegradable rings will
address this problem. Atrioventricular valve repair with this new
technology is feasible, with good early and midterm results.
Dr Oppido. In this series, we didn’t have any experience with
absorbable annuloplasty devices, but we anticipate that they may
be helpful in selected cases.
Dr Alain F. Carpentier (Paris, France). Dr Oppido, I congrat-
ulate you. When comparing this surgery to what I did in the past, it’s
obviously a tremendous improvement. The mortality has been
reduced significantly, and also you followed the guidelines. Obvi-
ously, there has been a lot of progress made. I do have two questions.
First, you mentioned the need to have a sort of annuloplasty
allowing the growth of the annulus, which is true for babies and peo-
ple younger than 10 years but not for people older than 10 years. So
do you have a different strategy, depending on the age, and partic-
ularly regarding using remodeling annuloplasty whenever possible,
when you don’t expect the need for growth of the annulus? That’s
my first question; I have another brief question afterward.
Dr Oppido. We used several techniques for annuloplasty, and
we strongly believe that every patient with mitral regurgitation
and annular dilation requires annuloplasty. So in the smaller patients
it should be feasible to use the sort of interrupted posterior annulo-
plasty with three-times–folded PTFE. After being positioned in the
posterior annulus, this band is cut in one or more points to allow
room for growth. Some other techniques, such as interrupted
mattress suture to compress the posterior annulus, were also done
in the smaller patients.
Dr Carpentier. No, my question is specifically, do you have an-
other strategy for older patients who can accommodate remodeling
annuloplasty, that is to say, a complete ring? I noticed that you haveune 2008
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Dpatients as old as 20 years, or at least beyond 15 years. Of course, it’s
a strategy more for an adult than for a young baby.
DrOppido.Yes, of course, in adult patients we implant an adult-
sized commercially available complete ring. We did it in 9 patients
in this series: posterior band in 5 patients and posterior complete
annuloplasty with PTFE in 7 patients.
Dr Carpentier. For my second question, how often have you
been using leaflet enlargement with pericardial patching?
Dr Oppido. Posterior leaflet was enlarged in 10 patients;
anterior leaflet was enlarged in 4 patients.
Dr Carpentier. And you haven’t seen any calcification of the
patch?
Dr Oppido. None at all.
Dr Carpentier. Thank you.
Dr Carlos Troconis (Miami, Fla). In your article, you did note
that the mitral valve was replaced in 4 cases, 1 early and 3 late. What
type of prosthesis did you use, mechanical or bioprosthesis? What
size and technique? What criteria did you chose?
DrOppido. The main goal of our policy, first of all, is to implant
a prosthesis only in the intra-annular position, so we tend to avoid
any different kind of implant, such as supra-annular and so on. So
we implanted in this series, as a primary replacement, 19-mm me-
chanical prostheses. And in the follow-up, during the reoperations,
we implanted two 21-mm mechanical prostheses and a homograft
valve as the fourth replacement. And it is interesting that we could
implant the two 21-mm prostheses in patients who were operated on
early in life; the annulus at the beginning, at the first operation, was
11 or 12 mm. That was a good result, I think.
Pedro J. del Nido (Boston, Mass). I also congratulate you. This
is a follow-up to your previous study on recurrent mitral regurgita-
tion. Now you are presenting more longitudinal information, and the
results seem to hold up over the years.
My question relates to an area in which we’ve become much more
interested, congenital mitral stenosis, particularly in the infant. It’s
a very different disease than regurgitation. Most of the problem appears
to be at the leaflet level. Images like the one that you showed, with ap-
parent short chordae, are in fact deceptive. In fact, if you put a light be-
hind those leaflets, you see that the chords are much, much longer;
they’re simply covered by a layer of what looks like endocardial tissue
that actually mats those chords together, and you can strip this tissue off
the chords. Van Praag demonstrated this more than 20 years ago.
My question relates to your management of mitral stenosis. It ap-
pears that your approach is primarily that of leaflet augmentation or
leaflet replacement, with pericardium or whatever available tissue
you have. Have you looked into leaflet thinning and removal ofThe Journal of Thorathe endocardial layer of tissue that actually creates much of the ste-
nosis? My concern with the replacement approach is that it still
leaves a funnellike mitral valve, and attempts at commissurotomy
are just going to lead to regurgitation. So might a different approach
be more applicable?
Dr Oppido. Thank you for your question. Yes, of course, I
showed just a few of the techniques we used. And especially in
patients with mitral stenosis and papillary muscle–commissural fu-
sion, we used several techniques, such as removing the excessive tis-
sue between the chordae, chordal fenestration (and when the
stenosis was at the papillary muscle level, papillary muscle fenestra-
tion), and when there was stenosis at the commissural level, com-
missurotomy. Of course, these were also integrated with the
posterior leaflet enlargement.
Dr del Nido. Can you comment about the durability of that
approach? In other words, how many of those patients required
reoperation?
Dr Oppido. You’re talking about what patients?
Dr del Nido. Patients with congenital mitral stenosis.
DrOppido. In this series, we had 11 patients with congenital mi-
tral stenosis. All are alive. Only 1 patient has moderate dysfunction,
and 1 patient has required replacement.
Dr Giovanni Stellin (Padua, Italy). I congratulate you on your
results. A similar experience from our group was presented 3 days
ago at the meeting of the World Society for Pediatric and Congenital
Heart Surgery. We have managed to reconstruct the whole spectrum
of the mitral valves disease.
You showed an image of a mitral valve malformation that you
have defined as papillary muscle–commissural fusion (Image shown
in Brizard,16 figure 124-3). According to Capentier’s classification,
what you have shown is not papillary muscle–commissural fusion;
it appears to me more like the typical hammock valve or perhaps
a mitral arcade, a malformation defined by two big papillary muscles
and small chordae. I therefore ask, how do you define a hammock
valve or a mitral arcade?
Dr Oppido. Of course, there is a wide, continuous spectrum
among those dysplastic valves, especially in the stenotic group;
however, what we define as hammock mitral valve is a mitral valve
with an extremely dysplastic subvalvular apparatus in which it is not
even possible to recognize papillary muscle in the tensor apparatus,
or with some dysmorphic papillary muscle displaced toward the
base of the heart, just behind the posterior leaflet, pulling both leaf-
lets toward the posterior part of the heart. That’s how we define ham-
mock valve; what we showed is for us papillary muscle–
commissural fusion, or short chordae syndrome.cic and Cardiovascular Surgery c Volume 135, Number 6 1321
